Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497418 | 0.94 | TSHR (0.48) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL10054624 | 0.84 | USP2 (0.43) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL24708172 | 0.82 | ALDH1A1 (0.30) | TSHRALDH1A1TDP1 | |
| SCHEMBL25896439 | 0.82 | KDM4E (0.41) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL19069731 | 0.82 | TSHR (0.56) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL21164831 | 0.79 | USP2 (0.46) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL10082514 | 0.79 | TSHR (0.33) | TSHRUSP2ALDH1A1TDP1 | |
| SCHEMBL2485099 | 0.79 | USP2 (0.50) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL22808901 | 0.78 | TSHR (0.46) | TSHRUSP2ALDH1A1KDM4ELMNA | |
| SCHEMBL13467249 | 0.76 | ALDH1A1 (0.38) | TSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2022266498-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | NEKTAR THERAPEUTICS (US) | 2022-12-22 | — | — | WO | disclosed |
| US-9023986-B2 | Glucose-dependent insulinotropic peptide analogs | HOFFMANN-LA ROCHE INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120302761-A1 | INTERMEDIATES USEFUL IN THE PREPARATION OF MALEIMIDE FUNCTIONALIZED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120094955-A1 | METHOD OF DISSOLVING AN OXIDIZED POLYSACCHARIDE IN AN AQUEOUS SOLUTION | ACTAMAX SURGICAL MATERIALS LLC (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094955-A1 | METHOD OF DISSOLVING AN OXIDIZED POLYSACCHARIDE IN AN AQUEOUS SOLUTION | SI, OGFOD1, OSTC | TSHR 3622/4885USP2 1278/4885ALDH1A1 777/4885 |
| US-20120302761-A1 | INTERMEDIATES USEFUL IN THE PREPARATION OF MALEIMIDE FUNCTIONALIZED POLYMERS | DERA, MMAB, PAICS | TSHR 4371/4885USP2 2406/4885ALDH1A1 74/4885 |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | DGKB, DGKG, DGKA | TSHR 4629/4885USP2 2976/4885ALDH1A1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.